恩替卡韦治疗慢性乙型肝炎病毒感染患者临床疗效分析

肖兰春+陈利

[摘要] 目的 对恩替卡韦治疗慢性乙型肝炎病毒感染患者临床疗效进行分析。方法 方便收集广东省兴宁市人民医院感染性疾病科2015年3月—2016年7月慢性乙型肝炎病毒感染患者50例随机分两组，每组25例。阿德福韦酯组采用阿德福韦酯进行治疗，恩替卡韦组采用恩替卡韦治疗。比较两组患者慢性乙型肝炎病毒感染治疗总有效率；用药后不良反应发生率、HBeAg转阴率；治疗前和治疗后患者HBeAg效价水平、HBV-DNA水平、ALT水平的差异。结果 恩替卡韦组患者慢性乙型肝炎病毒感染治疗总有效率96.00%高于阿德福韦酯组76.00%（P<0.05）；恩替卡韦组用药后不良反应发生率8.00%低于阿德福韦酯组28.00%、HBeAg转阴率96.00%高于阿德福韦酯组76.00%（P<0.05）；治疗前两组HBeAg效价水平、HBV-DNA水平、ALT水平比较差异无统计学意义（P>0.05）；治疗后恩替卡韦组HBeAg效价水平、HBV-DNA水平、ALT水平改善幅度更大（P<0.05）。結论 恩替卡韦治疗慢性乙型肝炎病毒感染患者临床疗效确切，可有效对肝炎病毒复制以及繁殖进行抑制，降低血清转氨酶水平，长期用药不良反应，安全性高，值得推广。

[关键词] 恩替卡韦；慢性乙型肝炎病毒感染患者；临床疗效

[中图分类号] R512 [文献标识码] A [文章编号] 1674-0742（2017）05（a）-0137-03

[Abstract] Objective To analyze the clinical efficacy of entecavir in the treatment of chronic hepatitis B virus infection. Methods A total of 50 patients with chronic hepatitis B virus infection were randomly divided into two groups（n=25） in the Department of Infectious Diseases in Xingning People's Hospital of Guangdong Province， from march 2015 to Tuly 2016. Adefovir dipivoxil was treated with adefovir dipivoxil， and entecavir was treated with entecavir. The HBeAg level of HBeAg， the level of HBeAg， the level of HBV-DNA and the level of ALT were compared before and after treatment. Results The total effective rate of chronic hepatitis B virus infection in patients with entecavir was 96.00% higher than that in adefovir dipivoxil group 76.00%（P<0.05）. The incidence of adverse reactions in entecavir group was 8.00% lower than that in adefovir dipivoxil group 28.00%（P<0.05）. There was no significant difference in HBeAg titer， HBV-DNA level and ALT level between the two groups before treatment （96.00% vs 76.00%）（P>0.05）. The level of HBeAg was significantly higher than that of adefovir dipivoxil group （P>0.05）. The level of HBeAg， the level of HBV-DNA and the level of ALT were significantly higher in the enantivacaine group （P<0.05）. Conclusion The efficacy of entecavir in the treatment of chronic hepatitis B virus infection is effective， it can effectively inhibit the replication and reproduction of hepatitis virus， reduce the level of serum transaminase， long-term use of side effects， high safety， worthy of promotion.

[Key words] Entecavir； Chronic hepatitis B virus infection； Clinical efficacy

慢性乙型肝炎是常见肝炎疾病，是HBV侵入机体后诱发机体免疫反应并对肝细胞造成间接损伤。慢性乙型肝炎发病机制复杂，免疫功能紊乱和病毒持续复制是发病重要原因。目前，临床对于慢性乙型肝炎多采用免疫调节、抗病毒、抗肝纤维化以及改善肝功能等治疗方法，其中抗病毒治疗是关键。恩替卡韦为新一代抗HBV核苷类似物，属于鸟嘌呤核苷酸类似物，不良反应少，服用方便，可有效抑制HBV复制。该研究方便收集2015年3月—2016年7月该院诊治的慢性乙型肝炎病毒感染患者50例随机分两组，分析了恩替卡韦治疗慢性乙型肝炎病毒感染患者临床疗效，现报道如下。

1 资料与方法

1.1 一般资料

方便收集该院诊治的慢性乙型肝炎病毒感染患者50例随机分两组。……